Adaptimmune secures $225m of new funding

By Aidan Gregory
02 Jun 2020

Adaptimmune Therapeutics, the New York-listed UK biopharmaceutical company focused on cancer treatments, has raised $225m to fund further clinical trials for its immunotherapy treatments.

The share sale came after the company’s stock closed 127% higher on Friday, May 29, after it issued a positive clinical update on its exploratory T-cell therapy to the annual meeting of the American Society for Clinical Oncology (ASCO).

The company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial